Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Haegarda Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - TennesseePolicy ID_CHS_21002025_1026

    C1 Esterase Inhibitor Subcutaneous (Human) Haegarda®

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_21002025_1026 alerts

    Get alerted when Policy ID_CHS_21002025_1026 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of subcutaneous human C1 esterase inhibitor (Haegarda) for prevention of hereditary angioedema attacks in eligible members who meet diagnostic, laboratory, treatment-response, and prescriber requirements, subject to plan terms and exclusions.

    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyC1 Esterase Inhibitor Subcutaneous (Human) Haegarda®
    Policy CodePolicy ID_CHS_21002025_1026
    Change TypeNo material clinical or coverage changes
    Effective DateDec 31, 202642d
    Next Review DateN/A
    Key ActionSubmit the required diagnostic laboratory or genetic documentation and ensure the prescriber specializes in hereditary angioedema management or consults with a specialist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Age 6+FDA-approved age threshold for routine HAE attack prophylaxis
    12 monthsInitial authorization period
    12 monthsContinuation authorization period
    ≥50%

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Example significant reduction in attack frequency required for continuation
    40 mg/dayHigh-dose cetirizine trial example for refractory angioedema
    TNState mandate requirements identified in the policy

    Coverage Criteria

    Initial therapy for hereditary angioedema

    Covered for prevention of hereditary angioedema attacks when all applicable requirements are met.

    Initial HAE prophylaxis requirements

    • No concurrent prophylaxis

      • The requested medication will not be used in combination with any other medication used for prophylaxis of hereditary angioedema attacks.
    • Diagnostic pathway

      • C1 inhibitor deficiency or dysfunction

        • C1-INH laboratory findings

          • C1-INH antigenic level is below the lower limit of normal as defined by the laboratory performing the test.
          • C1-INH antigenic level is normal and C1-INH functional level is below 50% or below the lower limit of normal as defined by the laboratory performing the test.Functional C1-INH <50% or below laboratory lower limit of normal
      • Normal C1 inhibitor

        • Supporting evidence

          • Genetic testing confirms a pathogenic variant in F12, angiopoietin-1, plasminogen, kininogen-1 (KNG1), heparan sulfate-glucosamine 3-O-sulfotransferase 6 (HS3ST6), or myoferlin (MYOF).
          • The member has a documented family history of angioedema and the member's angioedema was refractory to a trial of high-dose antihistamine therapy, such as cetirizine 40 mg per day or the equivalent, for at least one month.Cetirizine 40 mg/day or equivalent for at least 1 month
    • Exclusion of other causes

      • Other causes of angioedema have been ruled out, including angiotensin-converting enzyme inhibitor-induced angioedema, angioedema related to an estrogen-containing drug, and allergic angioedema.

    Continuation therapy

    Continuation of therapy is covered when all of the following criteria are met.

    Continuation therapy requirements

    • The member continues to meet all requirements in the coverage criteria section.
    • The member has experienced a significant reduction in the frequency of angioedema attacks since starting prophylactic treatment.Example significant reduction: ≥50% reduction in attack frequency
    • The member has reduced use of medications to treat acute attacks since starting prophylactic treatment.

    Coverage requires that Haegarda not be used in combination with any other medication for prophylaxis of hereditary angioedema (HAE) attacks. Concurrent use with another HAE prophylactic medication may result in noncoverage.

    Other causes of angioedema must be ruled out before coverage is authorized. Excluded or unresolved causes include ACE inhibitor–induced angioedema, angioedema related to an estrogen-containing drug, allergic angioedema, or another cause that has not been ruled out.

    Coverage is limited to routine prophylaxis to prevent hereditary angioedema attacks in patients 6 years of age and older. All other indications are considered experimental, investigational, and not medically necessary under this policy.

    Authorization and Provider Requirements

    Prior Authorization

    Initial Prior Authorization — HAE Prophylaxis

    A 12-month authorization may be granted for routine prophylaxis of hereditary angioedema (HAE) attacks when the requested medication will not be used with another medication for HAE prophylaxis and all diagnostic criteria are met.

    • Member has C1 inhibitor deficiency or dysfunction confirmed by laboratory testing, with either a low C1-INH antigenic level or a normal antigenic level and low C1-INH functional level.
    • Alternatively, member has normal C1 inhibitor confirmed by laboratory testing and either a qualifying pathogenic variant or documented family history of angioedema with angioedema refractory to high-dose antihistamine therapy for at least one month.
    • Other causes of angioedema must be ruled out, including ACE inhibitor-induced, estrogen-related, and allergic angioedema.
    • Medical Policy Manual Approved Archival: Do Not Implement until 12/31/26.
    Prior Authorization

    Continuation Prior Authorization

    A 12-month continuation authorization may be granted when the member continues to meet the coverage criteria and demonstrates a clinically meaningful response to prophylactic treatment.

    Hereditary Angioedema Background

    Hereditary angioedema (HAE) is characterized by recurrent attacks of swelling, including attacks associated with C1 inhibitor deficiency or dysfunction and HAE with normal C1 inhibitor. Haegarda is a subcutaneous human C1 esterase inhibitor indicated for routine prophylaxis to prevent HAE attacks in patients 6 years of age and older.

    Clinical Definitions

    Low C1-INH functional level
    Functional thresholdC1-INH functional level less than 50% qualifies as low.
    Laboratory referenceA C1-INH functional level below the lower limit of normal defined by the laboratory performing the test also qualifies as low.
    Diagnostic contextThe low functional level applies when the member has a normal C1-INH antigenic level and C1 inhibitor deficiency or dysfunction confirmed by laboratory testing.
    Pathogenic variant
    F12A pathogenic variant confirmed by genetic testing.
    Angiopoietin-1A pathogenic variant confirmed by genetic testing.

    Initial Haegarda Authorization Criteria

    Initial Haegarda authorization

    Authorization of 12 months may be granted for prevention of hereditary angioedema attacks when all requirements are met.

    Initial Haegarda requirements

    • No concurrent HAE prophylaxis

      • Haegarda will not be used in combination with any other medication used for prophylaxis of hereditary angioedema attacks.
    • Diagnostic pathway

      • C1 inhibitor deficiency or dysfunction

        • C1-INH laboratory findings

          • C1-INH antigenic level is below the lower limit of normal as defined by the laboratory performing the test.

    Continuation of Haegarda

    Continuation of Haegarda

    Authorization of 12 months may be granted for continuation of therapy when all criteria are met.

    Continuation requirements

    • The member meets all requirements in the coverage criteria section.
    • The member has experienced a significant reduction in the frequency of attacks since starting prophylactic treatment.Example: ≥50% reduction in attack frequency
    • The member has reduced use of medications to treat acute attacks since starting prophylactic treatment.
    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyC1 Esterase Inhibitor Subcutaneous (Human) Haegarda®
    Policy CodePolicy ID_CHS_21002025_1026
    Change TypeNo material clinical or coverage changes
    Effective DateDec 31, 202642d
    Next Review DateN/A
    Key ActionSubmit the required diagnostic laboratory or genetic documentation and ensure the prescriber specializes in hereditary angioedema management or consults with a specialist.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Provider RequirementsHereditary Angioedema BackgroundClinical DefinitionsInitial Haegarda Authorization CriteriaContinuation of Haegarda
    • Member meets all requirements in the coverage criteria section.
    • Member has experienced a significant reduction in attack frequency since starting prophylaxis, such as a reduction of at least 50%.
    • Member has reduced use of medications for acute attacks since starting prophylactic treatment.
    Documentation Required

    Qualified Specialist Prescriber

    The medication must be prescribed by, or prescribed in consultation with, a qualified specialist who manages hereditary angioedema (HAE).

    • Document the specialist prescriber or the specialist consultation in the authorization request.
    Documentation Required

    Initial Authorization Documentation

    For initial review, submit documentation establishing the member’s HAE diagnosis and the applicable laboratory, genetic, family-history, and treatment-response findings.

    • C1 inhibitor functional and antigenic protein levels.
    • If applicable, pathogenic variant testing for F12, angiopoietin-1, plasminogen, kininogen-1 (KNG1), HS3ST6, or myoferlin (MYOF).
    • If applicable, chart notes confirming a family history of angioedema and angioedema refractory to high-dose antihistamine therapy.
    Documentation Required

    Continuation Documentation

    For continuation review, provide chart notes demonstrating that prophylactic treatment has reduced the frequency of HAE attacks.

    • Document the change in attack frequency since treatment began, including a significant reduction such as at least 50% when applicable.
    • Document reduced use of medications for acute attacks.
    Denial Risk

    Noncovered Indications

    Haegarda is covered for routine prophylaxis to prevent HAE attacks in members age 6 years and older. Requests for other indications are considered experimental or investigational and not medically necessary.

    • Do not submit Haegarda for indications other than routine HAE attack prophylaxis.
    Denial Risk

    Concurrent HAE Prophylaxis

    Authorization may be denied when Haegarda is requested in combination with another medication used for prophylaxis of HAE attacks.

    • Confirm that the requested medication will not be used concurrently with another HAE prophylactic medication.
    Denial Risk

    Diagnostic Criteria Not Met

    Initial authorization may be denied when the member does not satisfy the required laboratory, genetic, family-history, antihistamine-response, or exclusion criteria for HAE.

    • Verify C1-INH antigenic and functional results against the laboratory’s reference ranges.
    • For normal C1 inhibitor, provide qualifying genetic testing or the required family-history and high-dose antihistamine-refractory documentation.
    • Document that other causes of angioedema have been ruled out.
    Denial Risk

    Insufficient Continuation Response

    Continuation authorization may be denied when prophylactic treatment does not produce a significant reduction in HAE attack frequency or reduce use of medications for acute attacks.

    • Submit chart notes comparing attack frequency before and after treatment.
    • Document the member’s reduced need for acute-attack treatment.
    Plasminogen
    A pathogenic variant confirmed by genetic testing.
    Kininogen-1 (KNG1)A pathogenic variant confirmed by genetic testing.
    HS3ST6A pathogenic variant in heparan sulfate-glucosamine 3-O-sulfotransferase 6 confirmed by genetic testing.
    MYOFA pathogenic variant in myoferlin confirmed by genetic testing.
    Refractory to high-dose antihistamine therapy
    Required responseAngioedema did not respond to a trial of high-dose antihistamine therapy.
    Example regimenCetirizine 40 mg per day, or an equivalent regimen.
    Minimum durationThe high-dose antihistamine regimen must be administered for at least one month.
  1. C1-INH antigenic level is normal and C1-INH functional level is below 50% or below the lower limit of normal as defined by the laboratory performing the test.Functional C1-INH <50% or below laboratory lower limit of normal
  2. Normal C1 inhibitor

    • Supporting evidence

      • Genetic testing confirms a pathogenic variant in F12, angiopoietin-1, plasminogen, kininogen-1 (KNG1), heparan sulfate-glucosamine 3-O-sulfotransferase 6 (HS3ST6), or myoferlin (MYOF).
      • The member has a documented family history of angioedema and the member's angioedema was refractory to a trial of high-dose antihistamine therapy, such as cetirizine 40 mg per day or the equivalent, for at least one month.Cetirizine 40 mg/day or equivalent for at least 1 month
  3. Exclusion of other causes

    • Other causes of angioedema have been ruled out, including angiotensin-converting enzyme inhibitor-induced angioedema, angioedema related to an estrogen-containing drug, and allergic angioedema.